# A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

> **NCT06113198** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Meningitis, Meningococcal

## Interventions

- **BIOLOGICAL:** rMenB+OMV NZ

## Key facts

- **NCT ID:** NCT06113198
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2026-09-07
- **Final completion:** 2027-02-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113198, "A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06113198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*